http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1340702-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a6399d236ec0ea3dc12007c4c82740e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 1989-02-22^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-08-10^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_458c416943b615170b8c7559389acca0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_603cedf1e10a61edaf344ce6481e495d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94892c97103caa91d352102b05380152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_093b105a82e33ea913b095eafe90f1a7 |
| publicationDate | 1999-08-10^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1340702-C |
| titleOfInvention | Derivatives of soluble t-4 |
| abstract | This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in Figure 6 from about +3 to about +185 fused to the amino acid sequence from about +351 to about +369. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in Figure 6 from about +3 to about +106 fused to the amino acid sequence from about +351 to about +369. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in Figure 6 from about +3 to about +185. This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier. |
| priorityDate | 1988-02-24^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1261.
| Next Page | Last Page |